PE20191108A1 - Inhibidores selectivos de jak1 - Google Patents
Inhibidores selectivos de jak1Info
- Publication number
- PE20191108A1 PE20191108A1 PE2019001401A PE2019001401A PE20191108A1 PE 20191108 A1 PE20191108 A1 PE 20191108A1 PE 2019001401 A PE2019001401 A PE 2019001401A PE 2019001401 A PE2019001401 A PE 2019001401A PE 20191108 A1 PE20191108 A1 PE 20191108A1
- Authority
- PE
- Peru
- Prior art keywords
- methyl
- fluoro
- ethyl
- selective inhibitors
- methylpyrimidin
- Prior art date
Links
- 229940124639 Selective inhibitor Drugs 0.000 title abstract 2
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 title 1
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 title 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 6
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 3
- 102000042838 JAK family Human genes 0.000 abstract 2
- 108091082332 JAK family Proteins 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- YWDLVFKNFPKVHE-LJQANCHMSA-N (2R)-N-[3-[2-(2-fluoro-3-methylsulfonylanilino)-5-methylpyrimidin-4-yl]-1H-indol-7-yl]-2-[4-(2-hydroxyethyl)piperazin-1-yl]propanamide Chemical compound FC1=C(C=CC=C1S(=O)(=O)C)NC1=NC=C(C(=N1)C1=CNC2=C(C=CC=C12)NC([C@@H](C)N1CCN(CC1)CCO)=O)C YWDLVFKNFPKVHE-LJQANCHMSA-N 0.000 abstract 1
- -1 3- (2- (2-fluoro-3- (methylsulfonyl) phenylamino) -5-methylpyrimidin-4-yl) -1H- indol-7-yl Chemical group 0.000 abstract 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 206010025323 Lymphomas Diseases 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 239000000460 chlorine Chemical group 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 150000002431 hydrogen Chemical group 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invencion se refiere a un compuesto de formula I y sales aceptables del mismo, donde: R1, R3, y R4 son individualmente hidrogeno o metilo; R2 es hidrogeno, metilo o -CH2CH2OH; n es 1 o 2; R5 es metilo, etilo o -CH 2OR8; R6 es metilo, cloro o fluor; R7 es metilo, etilo y ciclopropilo; y R8 es metilo, etilo o bencilo. Son compuestos preferidos: (R) -N- (3- (2 - ((2-fluoro-3- (metilsulfonil) fenil) amino) -5-metilpirimidin-4-il) -1H- indol-7-il) -2- (4 - (2-hidroxietil) piperazin-1-il) propanamida; (R) -N- (3- (2- (2-fluoro-3- (metilsulfonil) fenilamino) -5-metilpirimidin-4-il) -1H- indol-7-il) -2- (4-metilpiperazina-1-il) propanamida; entre otros. Tambien se refiere a una composicion farmaceutica. Dichos compuestos son inhibidores selectivos de la cinasa asociada a Janus (JAK1) utiles en el tratamiento de leucemia, linfoma, entre otros.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762447057P | 2017-01-17 | 2017-01-17 | |
| PCT/EP2018/051038 WO2018134213A1 (en) | 2017-01-17 | 2018-01-16 | Jak1 selective inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20191108A1 true PE20191108A1 (es) | 2019-08-26 |
Family
ID=61024756
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2019001401A PE20191108A1 (es) | 2017-01-17 | 2018-01-16 | Inhibidores selectivos de jak1 |
Country Status (39)
| Country | Link |
|---|---|
| US (3) | US10961228B2 (es) |
| EP (2) | EP3571192B1 (es) |
| JP (3) | JP6986086B2 (es) |
| KR (2) | KR102659213B1 (es) |
| CN (2) | CN110461830B (es) |
| AR (1) | AR110753A1 (es) |
| AU (1) | AU2018209667B2 (es) |
| CA (1) | CA3049175A1 (es) |
| CL (1) | CL2019001993A1 (es) |
| CO (1) | CO2019007888A2 (es) |
| CR (1) | CR20190332A (es) |
| DK (1) | DK3571192T3 (es) |
| DO (1) | DOP2019000184A (es) |
| EA (1) | EA037067B1 (es) |
| EC (1) | ECSP19051352A (es) |
| ES (1) | ES2938648T3 (es) |
| FI (1) | FI3571192T3 (es) |
| HR (1) | HRP20230069T1 (es) |
| HU (1) | HUE061064T2 (es) |
| IL (1) | IL267851B (es) |
| JO (1) | JOP20190174B1 (es) |
| LT (1) | LT3571192T (es) |
| MA (1) | MA47301B1 (es) |
| MX (2) | MX390625B (es) |
| MY (1) | MY199735A (es) |
| NI (1) | NI201900077A (es) |
| NZ (1) | NZ756069A (es) |
| PE (1) | PE20191108A1 (es) |
| PH (1) | PH12019501639B1 (es) |
| PL (1) | PL3571192T3 (es) |
| PT (1) | PT3571192T (es) |
| RS (1) | RS63981B1 (es) |
| SG (1) | SG11201906222WA (es) |
| SI (1) | SI3571192T1 (es) |
| SM (1) | SMT202300051T1 (es) |
| TW (1) | TWI753089B (es) |
| UA (1) | UA124246C2 (es) |
| WO (1) | WO2018134213A1 (es) |
| ZA (1) | ZA201906875B (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201906222WA (en) | 2017-01-17 | 2019-08-27 | Astrazeneca Ab | Jak1 selective inhibitors |
| DK3514153T3 (da) * | 2017-01-26 | 2021-09-27 | Hanmi Pharm Ind Co Ltd | Pyrimidinforbindelse og farmaceutisk anvendelse deraf |
| AU2019304014B2 (en) * | 2018-07-18 | 2022-08-18 | Astrazeneca Ab | A xinafoate salt of a jak inhibiting compound |
| KR101954370B1 (ko) | 2018-07-25 | 2019-03-05 | 한미약품 주식회사 | 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물 |
| CA3113732C (en) * | 2018-09-21 | 2023-07-11 | Shanghai Ennovabio Pharmaceuticals Co., Ltd. | Aromatic heterocyclic compound with kinase inhibitory activity |
| PE20212153A1 (es) | 2019-02-22 | 2021-11-09 | Hanmi Pharm Ind Co Ltd | Composicion farmaceutica que comprende un inhibidor de flt3 y un agente hipometilante para tratar la leucemia mieloide aguda |
| US20220220096A1 (en) * | 2019-04-19 | 2022-07-14 | Dizal (Jiangsu) Pharmaceutical Co., Ltd. | Jak1 selective kinase inhibitor |
| WO2020262974A1 (ko) | 2019-06-27 | 2020-12-30 | 한미약품 주식회사 | Flt3 저해제 및 화학치료제를 포함하는 급성 골수성 백혈병 치료용 약학적 조성물 |
| US12435084B2 (en) | 2020-04-09 | 2025-10-07 | Eli Lilly And Company | Indazole derivatives as inhibitors of SARM1 |
| JP7613778B2 (ja) * | 2020-11-26 | 2025-01-15 | 科輝智薬（深▲セン▼）新薬研究中心有限公司 | アミド化合物、医薬組成物およびその使用 |
| US12240836B2 (en) | 2022-07-05 | 2025-03-04 | Dong-A St Co., Ltd. | Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof |
| CN115260128B (zh) * | 2022-09-21 | 2022-12-09 | 苏州凯瑞医药科技有限公司 | 一种新型jak抑制剂关键中间体的制备方法 |
| EP4648776A1 (en) * | 2023-01-11 | 2025-11-19 | Pfizer Inc. | Compositions and methods for the treatment and/or prevention of type 1 diabetes |
| CN115974845B (zh) * | 2023-01-19 | 2024-09-20 | 奥锐特药业股份有限公司 | 奥希替尼中间体的制备方法 |
| WO2024192350A1 (en) * | 2023-03-16 | 2024-09-19 | Incyte Corporation | Jak1 pathway inhibitors for the treatment of asthma |
| GB202316063D0 (en) | 2023-10-20 | 2023-12-06 | Astrazeneca Ab | Dosing regime |
| GB202403369D0 (en) | 2024-03-08 | 2024-04-24 | Astrazeneca Ab | Process and intermediates for the production of a jak1 inhibitor |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2580913A1 (en) * | 2004-10-13 | 2006-04-27 | Wyeth | N-benzenesulfonyl substituted anilino-pyrimidine analogs |
| GB2431927B (en) * | 2005-11-04 | 2010-03-17 | Amira Pharmaceuticals Inc | 5-Lipoxygenase-activating protein (FLAP) inhibitors |
| CN101421250A (zh) * | 2006-01-30 | 2009-04-29 | 埃克塞里艾克西斯公司 | 作为jak-2调节剂的4-芳基-2-氨基-嘧啶或4-芳基-2-氨基烷基-嘧啶及包含它们的药物组合物 |
| WO2008097930A1 (en) * | 2007-02-05 | 2008-08-14 | Amira Pharmaceuticals, Inc. | Reverse indoles as 5-lipoxygenase-activating protein (flap) inhibitors |
| WO2009045700A2 (en) * | 2007-10-05 | 2009-04-09 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (flap) inhibitors |
| WO2009046416A1 (en) * | 2007-10-05 | 2009-04-09 | Targegen Inc. | Anilinopyrimidines as jak kinase inhibitors |
| GB0805477D0 (en) | 2008-03-26 | 2008-04-30 | Univ Nottingham | Pyrimidines triazines and their use as pharmaceutical agents |
| UA110324C2 (en) * | 2009-07-02 | 2015-12-25 | Genentech Inc | Jak inhibitory compounds based on pyrazolo pyrimidine |
| RS57219B1 (sr) | 2010-03-10 | 2018-07-31 | Incyte Holdings Corp | Piperidin-4-il azetidin derivati kao inhibitori jak1 |
| TW201217387A (en) * | 2010-09-15 | 2012-05-01 | Hoffmann La Roche | Azabenzothiazole compounds, compositions and methods of use |
| AU2014339897A1 (en) | 2013-10-24 | 2016-04-21 | Abbvie Inc. | JAK1 selective inhibitor and uses thereof |
| US9714236B2 (en) * | 2015-09-25 | 2017-07-25 | Astrazeneca Ab | Compounds and methods for inhibiting JAK |
| SG11201906222WA (en) * | 2017-01-17 | 2019-08-27 | Astrazeneca Ab | Jak1 selective inhibitors |
-
2018
- 2018-01-16 SG SG11201906222WA patent/SG11201906222WA/en unknown
- 2018-01-16 MX MX2019008435A patent/MX390625B/es unknown
- 2018-01-16 KR KR1020237032917A patent/KR102659213B1/ko active Active
- 2018-01-16 PT PT187012968T patent/PT3571192T/pt unknown
- 2018-01-16 HR HRP20230069TT patent/HRP20230069T1/hr unknown
- 2018-01-16 ES ES18701296T patent/ES2938648T3/es active Active
- 2018-01-16 EA EA201991700A patent/EA037067B1/ru unknown
- 2018-01-16 CN CN201880018044.3A patent/CN110461830B/zh active Active
- 2018-01-16 HU HUE18701296A patent/HUE061064T2/hu unknown
- 2018-01-16 JO JOP/2019/0174A patent/JOP20190174B1/ar active
- 2018-01-16 CA CA3049175A patent/CA3049175A1/en active Pending
- 2018-01-16 LT LTEPPCT/EP2018/051038T patent/LT3571192T/lt unknown
- 2018-01-16 PL PL18701296.8T patent/PL3571192T3/pl unknown
- 2018-01-16 US US16/478,168 patent/US10961228B2/en active Active
- 2018-01-16 SM SM20230051T patent/SMT202300051T1/it unknown
- 2018-01-16 SI SI201830849T patent/SI3571192T1/sl unknown
- 2018-01-16 KR KR1020197023855A patent/KR102585048B1/ko active Active
- 2018-01-16 NZ NZ756069A patent/NZ756069A/en unknown
- 2018-01-16 EP EP18701296.8A patent/EP3571192B1/en active Active
- 2018-01-16 RS RS20230130A patent/RS63981B1/sr unknown
- 2018-01-16 PE PE2019001401A patent/PE20191108A1/es unknown
- 2018-01-16 WO PCT/EP2018/051038 patent/WO2018134213A1/en not_active Ceased
- 2018-01-16 AU AU2018209667A patent/AU2018209667B2/en active Active
- 2018-01-16 DK DK18701296.8T patent/DK3571192T3/da active
- 2018-01-16 MY MYPI2019004083A patent/MY199735A/en unknown
- 2018-01-16 UA UAA201909176A patent/UA124246C2/uk unknown
- 2018-01-16 EP EP22209765.1A patent/EP4219470A1/en active Pending
- 2018-01-16 MA MA47301A patent/MA47301B1/fr unknown
- 2018-01-16 FI FIEP18701296.8T patent/FI3571192T3/fi active
- 2018-01-16 CN CN202211243959.9A patent/CN115925693B/zh active Active
- 2018-01-16 PH PH1/2019/501639A patent/PH12019501639B1/en unknown
- 2018-01-16 CR CR20190332A patent/CR20190332A/es unknown
- 2018-01-16 JP JP2019537377A patent/JP6986086B2/ja active Active
- 2018-01-17 AR ARP180100104A patent/AR110753A1/es unknown
- 2018-01-17 TW TW107101685A patent/TWI753089B/zh active
-
2019
- 2019-07-04 IL IL267851A patent/IL267851B/en unknown
- 2019-07-15 CL CL2019001993A patent/CL2019001993A1/es unknown
- 2019-07-15 MX MX2022002976A patent/MX2022002976A/es unknown
- 2019-07-17 DO DO2019000184A patent/DOP2019000184A/es unknown
- 2019-07-17 NI NI201900077A patent/NI201900077A/es unknown
- 2019-07-17 EC ECSENADI201951352A patent/ECSP19051352A/es unknown
- 2019-07-23 CO CONC2019/0007888A patent/CO2019007888A2/es unknown
- 2019-10-18 ZA ZA2019/06875A patent/ZA201906875B/en unknown
-
2021
- 2021-03-01 US US17/188,097 patent/US11897869B2/en active Active
- 2021-11-26 JP JP2021191658A patent/JP7394820B2/ja active Active
-
2023
- 2023-10-20 JP JP2023180744A patent/JP7626819B2/ja active Active
- 2023-12-13 US US18/538,067 patent/US12473272B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20191108A1 (es) | Inhibidores selectivos de jak1 | |
| MX2023000085A (es) | Compuestos antiproliferativos y metodos para utilizarlos. | |
| PE20170705A1 (es) | Nuevos compuestos como inhibidores de ret (reorganizado durante la transfeccion) | |
| PE20211375A1 (es) | Compuestos de 4-aminoisoindolina-1,3-diona sustituidos y su uso para el tratamiento de linfoma | |
| PE20210128A1 (es) | Inhibidores de la ectonucleotido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos | |
| PE20170268A1 (es) | Compuestos de heteroarilo para la inhibicion de cinasa | |
| MX2010006260A (es) | Composiciones orales de abt-263 para tratar cancer. | |
| HRP20241768T1 (hr) | Heterociklički spoj | |
| PE20090773A1 (es) | Derivados de morfolina pirimidina | |
| PE20151274A1 (es) | Inhibidores de erk y sus usos | |
| UY35998A (es) | 1-(3-(tert-BUTIL)1-(p-TOLIL)-1H-PIRAZOL-5-IL)-3-(4-((2-((6-ETILPIRAZIN-2-IL)AMINO)PIRIDIN-4-IL)METOXI)NAFTALEN-1-IL) UREA Y SUS SALES DERIVADAS FARMACÉUTICAMENTE ACEPTABLES, COMO INHIBIDORES DE P38 M AP QUINASA | |
| PE20181015A1 (es) | 2-amino-3-fluoro-3-(fluorometil)-6-meti-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 | |
| SA519410253B1 (ar) | Erk1/2 مشتق 6- بيريميدين أيزوإندول كمثبط | |
| PE20141700A1 (es) | Compuestos de 2-(2,4,5-anilino sustituido) pirimidina | |
| PE20161236A1 (es) | Compuesto de triazina y su uso para fines medicos | |
| PE20161393A1 (es) | Heteroaril amidas como inhibidores de agregacion de proteina | |
| PE20161443A1 (es) | Compuestos | |
| PE20210373A1 (es) | Compuestos de pirimidina y composiciones farmaceuticas para prevenir o tratar canceres que incluyen los mismos | |
| MX374541B (es) | Sales de clorhidrato de n-(cianometil)-4-(2-(4-morfolinofenilamino) pirimidin-4-il)benzamida. | |
| PE20061150A1 (es) | Derivados de n-(n-sulfonilaminoarilmetil)ciclopropanocarboxamida sustituidos como antagonistas del receptor vainilloide tipo 1 (vdr1) | |
| PE20181017A1 (es) | Compuestos heteroarilo y su uso como farmacos terapeuticos | |
| PE20200960A1 (es) | Inhibidor de receptor del factor de crecimiento epidermico | |
| JOP20190053A1 (ar) | مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط | |
| PE20200848A1 (es) | Compuestos derivados de fenilpiridina con actividad dual anti-btk y anti-itk y composiciones farmaceuticas que los contienen | |
| CY1111102T1 (el) | 2-(4-κυανοφαινυλ)-6-υδροξυλαμινοπυριμιδινες που αναστελλουν τον hiv |